David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$520M |
| 2 |
Accenture
ACN
|
+$474M |
| 3 |
Intel
INTC
|
+$436M |
| 4 |
Adobe
ADBE
|
+$318M |
| 5 |
Northrop Grumman
NOC
|
+$262M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.23B |
| 2 |
Apple
AAPL
|
+$900M |
| 3 |
Microsoft
MSFT
|
+$733M |
| 4 |
Netflix
NFLX
|
+$637M |
| 5 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$542M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.68% |
| 2 | Consumer Discretionary | 10.14% |
| 3 | Financials | 7.13% |
| 4 | Healthcare | 6.41% |
| 5 | Industrials | 4.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DCH
2951
Dauch Corp
DCH
$1.52B
| $1.18M | ﹤0.01% |
169,405
+139,314
| +463% | +$1.03M |
|
|
KALV
2952
DELISTED
KalVista Pharmaceuticals
KALV
| $1.18M | ﹤0.01% |
100,061
+12,968
| +15% | +$151K |
|
2953
Intapp
INTA
$3.09B
| $1.18M | ﹤0.01% |
32,059
-119,702
| -79% | -$4.07M |
|
2954
KT
KT
$9.36B
| $1.18M | ﹤0.01% |
85,997
+54,301
| +171% | +$716K |
|
2955
MYR Group
MYRG
$4.87B
| $1.17M | ﹤0.01% |
8,658
-1,900
| -18% | -$297K |
|
2956
CEMIG Preferred Shares
CIG
$5.66B
| $1.17M | ﹤0.01% |
666,675
+63,319
| +10% | +$121K |
|
2957
Bruker
BRKR
$8.69B
| $1.17M | ﹤0.01% |
18,372
-60,155
| -77% | -$4.53M |
|
2958
CALL
Academy Sports + Outdoors
ASO
$2.7B
| $1.17M | ﹤0.01% |
+21,900
| New | +$1.24M |
|
2959
Xeris Biopharma Holdings
XERS
$1.58B
| $1.17M | ﹤0.01% |
518,024
-188,987
| -27% | -$381K |
|
2960
Dimensional US Large Cap Value ETF
DFLV
$7.08B
| $1.17M | ﹤0.01% |
+40,307
| New | +$1.17M |
|
2961
MasterCraft Boat Holdings
MCFT
$587M
| $1.16M | ﹤0.01% |
61,639
+16,201
| +36% | +$337K |
|
2962
Steris
STE
$23.1B
| $1.16M | ﹤0.01% |
+5,298
| New | +$1.15M |
|
2963
CALL
DHT Holdings
DHT
$2.95B
| $1.16M | ﹤0.01% |
+100,000
| New | +$1.17M |
|
|
BNT
2964
Brookfield Wealth Solutions
BNT
$12.5B
| $1.16M | ﹤0.01% |
41,648
+7,950
| +24% | +$221K |
|
2965
PUT
Boston Scientific
BSX
$69.8B
| $1.16M | ﹤0.01% |
+15,000
| New | +$1.1M |
|
2966
Essent Group
ESNT
$6.25B
| $1.15M | ﹤0.01% |
+20,518
| New | +$1.14M |
|
|
GOOS
2967
CALL
Canada Goose Holdings
GOOS
$793M
| $1.15M | ﹤0.01% |
89,000
+2,100
| +2% | +$26.1K |
|
2968
PUT
Rapid7
RPD
$795M
| $1.15M | ﹤0.01% |
+26,600
| New | +$1.11M |
|
2969
CALL
Regal Rexnord
RRX
$11B
| $1.15M | ﹤0.01% |
8,500
| – | – |
|
|
HCP
2970
PUT
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
| $1.15M | ﹤0.01% |
34,100
+2,100
| +7% | +$65.3K |
|
2971
Saic
SAIC
$5.39B
| $1.15M | ﹤0.01% |
9,742
+7,178
| +280% | +$909K |
|
2972
PUT
NovoCure
NVCR
$2.08B
| $1.14M | ﹤0.01% |
66,700
+25,400
| +62% | +$447K |
|
|
BPMC
2973
PUT
DELISTED
Blueprint Medicines
BPMC
| $1.14M | ﹤0.01% |
10,600
+3,300
| +45% | +$330K |
|
2974
iShares MSCI Canada ETF
EWC
$6.91B
| $1.14M | ﹤0.01% |
30,788
+20,764
| +207% | +$781K |
|
2975
Revolution Medicines
RVMD
$46.2B
| $1.14M | ﹤0.01% |
29,294
-44,363
| -60% | -$1.66M |
|
Similar funds
David Shaw's Q2 2024 Portfolio in Review
As of Q2 2024, David Shaw held 4,975 positions worth $107B, down 8.5% from $117B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
David Shaw withdrew a net $20B in Q2 2024, closing 541 positions and reducing 1,567 holdings. Its most notable exit was Pioneer Natural Resource Co., an estimated $542M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, David Shaw opened a new position in iShares JPMorgan USD Emerging Markets Bond ETF worth $258M.
- David Shaw's largest Q2 2024 buy was iShares JPMorgan USD Emerging Markets Bond ETF: 2,917,600 shares worth $258M.
- David Shaw added most to Broadcom in Q2 2024, an estimated $520M increase.
- David Shaw's biggest Q2 2024 reduction was NVIDIA, cutting an estimated $1.23B.
- David Shaw fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $542M.
- David Shaw's ten largest holdings make up 11% of its $107B portfolio in Q2 2024.
- David Shaw opened 693 new positions and closed 541 in Q2 2024.
- David Shaw's portfolio value fell 8.5% quarter-over-quarter to $107B.
Based on D.E. Shaw & Co's 13F filing for Q2 2024, filed 14 Aug 2024.